Perfil de resistencia de rilpivirina

Azijn, 2010, TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1, Antimicrob Agents Chemother, 54, 718, 10.1128/AAC.00986-09 Das, 2008, High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations, Proc Natl Acad Sci USA, 105, 1466, 10.1073/pnas.0711209105 Lansdon, 2010, Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design, J Med Chem, 53, 4295, 10.1021/jm1002233 Molina, 2011, Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind activecontrolled trial, Lancet, 378, 238, 10.1016/S0140-6736(11)60936-7 Cohen, 2011, Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial, Lancet, 378, 229, 10.1016/S0140-6736(11)60983-5 Cohen, 2012, Efficacy and safety of rilpivirine (TMC-278) versus efavirenz at 48 weeks in treatment-naïve HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials, J Acquir Immune Defic Syndr, 60, 33, 10.1097/QAI.0b013e31824d006e Rimsky, 2012, Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis, J Acquir Immune Defic Syndr, 59, 39, 10.1097/QAI.0b013e31823df4da Cohen, 2012, STaR Study: Single-Tablet Regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naïve adults - week 48 Results Haddad, 2011, Impact of HIV-1 reverse transcriptase E138 mutations on rilpivirine drug susceptivility Haddad, 2012, Mutation Y188L of HIV-1 reverse transcriptase is strongly associated with reduced susceptibility to rilpivirine Crauwels, 2010, Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral naïve, HIV-1-infected patients in ECHO and THRIVE, 186 Llibre, 2010, Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1–infected patients with virological failure, Clin Infect Dis, 50, 872, 10.1086/650732 Asahchop, 2011, Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes, Antimicrob Agents Chemother, 55, 600, 10.1128/AAC.01192-10 Vingerhoets, 2013, Preexisting mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virologic response, Antivir Ther, 18, 253, 10.3851/IMP2358 Kulkarni, 2012, The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness, J Acquir Immune Defic Syndr, 59, 47, 10.1097/QAI.0b013e31823aca74 Hu, 2012, Impact of interaction of reverse transcriptase mutations E138K and M184I/V on rilpivirine susceptibility and viral fitness of HIV Singh, 2012, Biochemical mechanism of HIV-1 resistance to rilpivirine, J Biol Chem, 287, 38110, 10.1074/jbc.M112.398180 Hu, 2011, Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1, J Virol, 85, 11309, 10.1128/JVI.05578-11 Xu, 2011, Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations, J Virol, 85, 11300, 10.1128/JVI.05584-11 Fourati, 2012, E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure, AIDS, 26, 1619, 10.1097/QAD.0b013e3283560703 Asahchop, 2012, Distinct resistance patterns to etravirine and rilpivirine in viruses containing NNRTI mutations at baseline, AIDS Xu, 2012, Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase, J Virol, 86, 12983, 10.1128/JVI.02005-12 Johnson, 2013, Update of the drug resistance mutations in HIV-1: March 2013, Top Antivir Med, 21, 6 Tibotec Pharmaceuticals. Edurant™ (rilpivirine) tablets: US prescribing information. Disponible en: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf European Medicines Agency. Edurant® 25mg film-coated tablets: summary of product characteristics. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdf Stanford University Drug Resistance Database [consultado 19-2-2013]. Disponible en: http://hivdb.stanford.edu/ Anta, 2013, Resistance Platform of the Spanish AIDS Research Network. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies, AIDS, 27, 81, 10.1097/QAD.0b013e3283584500 HIV French Resistance, French ANRS (National Agency for AIDS Research) AC11 Resistance Group. September 2012- Version n.° 22 [consultado 19-2-2013]. Disponible en: http://hivfrenchresistance.org/ Lambert-Niclot, 2013, Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naïve patients infected with B and non-B subtype HIV-1 viruses, J Antimicrob Chemother, 10.1093/jac/dkt003 Picchio, 2012, Prevalence of rilpivirine resistance-associated mutations in US samples received for routine resistance testing Arastéh, 2009, Shortterm randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy, Antivir Ther, 14, 713, 10.1177/135965350901400506